Key Players
Competitive Landscape
Four supplier models compete in the cell therapy packaging market: integrated biologistics groups, primary-container specialists, cell-processing platform companies and temperature-controlled packaging specialists.
Investment has moved in two directions since 2025, toward wider biologistics networks and commercially adopted primary containers. Cryoport completed a roughly USD 200 million CRYOPDP divestiture and DHL partnership in June 2025. BioLife Solutions reported in May 2026 that CellSeal cryogenic vials and hPL products were embedded in four approved therapies. Therapy developers compare qualification depth and service reach, then evaluate price across regulated distribution networks.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Cryoport completed the CRYOPDP divestiture and DHL partnership in June 2025 for approximately USD 200 million. | Therapy sponsors require wider lane coverage without managing separate specialty couriers. | Specialist cryogenic platforms are linking with global logistics networks. | Integrated customs, transport and temperature-control services across EMEA and APAC. |
| Cryoport launched a 55,000-square-foot Paris supply-chain center in October 2025. | European therapy programs need nearby storage and qualified shipping support. | Biologistics capacity is moving closer to advanced-therapy manufacturing clusters. | Regional biostorage, kitting, labeling and therapy fulfillment services. |
| BioLife Solutions reported in May 2026 that CellSeal cryogenic vials and hPL products were embedded in four approved therapies. | Commercial manufacturers need final-dose containers with established regulatory history. | Primary containers gain value through use across approved therapy workflows. | Validation support and recurring vial sales for late-stage and commercial programs. |
Avantor and Azenta Life Sciences compete through single-use workflow components and automated sample-storage services, but neither announced a directly relevant packaging development during 2025-2026.
Source: Future Market Insights, Cell Therapy Packaging and Temperature-Controlled Packaging Solutions Market Reports, 2026-2036.
Cryoport and BioLife cover cryogenic transport with primary containment and biopreservation, while Thermo Fisher and Ori Biotech connect those controls with scalable fill-and-finish and closed manufacturing systems.
Who leads the cell therapy packaging market?
Cryoport leads on certified biologistics coverage following its Paris expansion and DHL partnership during 2025. BioLife Solutions competes through CellSeal containers and biopreservation products used across closed cell therapy workflows worldwide.
Which suppliers have documented qualification or quality approvals?
Cryoport reports ISO 21973:2020 and ISO 9001:2015 certification across cell therapy transport operations. BioLife Solutions reports ISO 13485:2016 and ISO 9001:2015 at sites supporting cell-processing and biopreservation products.
Which companies provide cryogenic and single-use packaging products?
BioLife Solutions supplies CellSeal cryogenic vials and closed connectors for patient-linked materials during storage and transfer. Avantor provides single-use fluid-handling assemblies, while Cryoport supplies cryogenic shipping systems for regulated cell therapy lanes.
Which suppliers serve North America and Europe?
Cryoport operates global supply-chain centers across North America and Europe for regulated therapy programs worldwide. CSafe and Azenta maintain multi-region cold-chain or biostorage coverage across clinical and commercial therapy networks.
Representative Company Overview
| Company | Positioning | Verified market-relevant capabilities |
|---|---|---|
| Cryoport Systems, LLC | Global | Cryogenic shipping systems, biostorage, labeling and condition monitoring. |
| Thermo Fisher Scientific Inc. | Global | Fill-and-finish systems for scalable cell therapy formulation and filling. |
| Sartorius AG | Global | Closed automated cell therapy production and quality-control platforms. |
| Avantor, Inc. | 180 countries | Single-use assemblies, fluid-handling materials and bioprocess support. |
| Azenta Life Sciences | Global | Automated cryogenic storage, biorepository services and sample handling. |
| CSafe Global | Global | Active and passive temperature-controlled shippers with shipment tracking. |
| Ori Biotech Ltd. | United States and United Kingdom | Closed automated cell therapy manufacturing with integrated hardware, consumables and digital controls. |
| BioLife Solutions, Inc. | Global distribution network | CellSeal cryogenic containers, biopreservation media and automated thawing systems. |
Research Methodology
These companies illustrate market structure without forming a ranking among verified cell therapy packaging participants. Inclusion requires current evidence that each company supplies primary containers or single-use interfaces for regulated cell therapy programs. Cryogenic transport and biostorage capabilities also require current supporting public records from official company sources. Company filings and official releases directly establish market-relevant capabilities for every participant in this section. Certification records remain assigned to the named site or legal entity directly holding the approval.
